Cerebrolysin: What It Is and Its U.S. Regulatory Status

What is Cerebrolysin?

Cerebrolysin is a prescription product used in some countries outside the United States. It is not FDA-approved, and no approved medicine in the United States contains it.

It is not a single peptide. It is a mixture of low-molecular-weight peptides and amino acids produced from purified proteins taken from pig (porcine) brain tissue. It is made by EVER Pharma, a company headquartered in Austria, and is supplied as a sterile solution for non-oral use.

The manufacturer lists uses such as stroke, head injury and certain forms of dementia in the countries where it is registered. A 2023 Cochrane review described it as widely used for acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries.

How it is thought to work

Because Cerebrolysin is a mixture, it has no single defined active ingredient or mechanism. It is described as having potential neuroprotective (nerve-protecting) properties. That idea comes mainly from laboratory and animal research, and it has not been established as a mechanism in people.

Research and development history

Cerebrolysin has been tested in randomized trials, most of them in stroke. The Cochrane review, updated in October 2023, pooled seven randomized controlled trials with 1,773 people who started Cerebrolysin, or a similar product called Cortexin made from cattle brain, within 48 hours of an ischaemic stroke.

The reviewers found moderate-certainty evidence that these products probably make little or no difference to deaths from any cause. They also found moderate-certainty evidence of a possible increase in non-fatal serious adverse events with Cerebrolysin, based on three trials with 1,335 participants. None of the trials reported on death or dependence at the end of follow-up, and the manufacturer supported three of the multicenter studies.

The Cochrane review looked only at acute ischaemic stroke. It does not cover the other uses listed by the manufacturer, and none of those uses has been approved by the FDA.

U.S. regulatory status

Current status: Not FDA-approved.

Cerebrolysin has not gone through the FDA review that a drug must pass before it can be marketed in the United States. Approval in another country does not make a drug approved here; each product must go through its own FDA review.

Cerebrolysin does not appear on the FDA's May 2026 lists of bulk substances nominated for pharmacy compounding, and it is not on the list of bulk substances pharmacies may use. Products sold online under the name are not approved medicines, and the FDA has not reviewed their identity, purity or sterility.

Documented safety information

Because it is not approved in the United States, there is no FDA label for Cerebrolysin. In the pooled stroke trials, the Cochrane reviewers found little or no difference in the total number of people with adverse events, but the possible increase in non-fatal serious adverse events was the clearest safety signal.

Sport

Cerebrolysin is not named on the World Anti-Doping Agency (WADA) 2026 Prohibited List.

Why Peptide Labs does not sell Cerebrolysin

Peptide Labs does not sell this compound. This page is general information, not medical advice. Our Peptide Guide exists to explain what these compounds are and how they are regulated, not to supply them.

Anyone with questions about Cerebrolysin should speak with a licensed healthcare provider, who can explain the current evidence and the legal status in plain terms.

Related reading

See the full list of compound profiles in the Peptide Guide. Other profiles in our cognitive group include Semax and dihexa. For background on how these compounds are regulated, read whether peptides are legal in the U.S.